OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
ConclusionOCE-205 was safe and well tolerated, with a pharmacodynamic profile achieving submaximal partial agonism consistent with mixed agonism-antagonism of the V1a receptor. OCE-205 shows promise as a treatment for some complications of end-stage liver disease.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Gastroenterology | Hypertension | Liver | Liver Disease | Pain | Study | Urology & Nephrology